Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

References

• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D’Haese JG, Schloesser H, et al. Advances in cancer immunotherapy 2019 – latest trends. J Exp Clin Cancer Res. 2019;38(1):268. doi:10.1186/s13046-019-1266-0.
   PubMed Web of Science ®Google Scholar
• Schmidt C. The benefits of immunotherapy combinations. Nature. 2017;552(7685):S67–S69. doi:10.1038/d41586-017-08702-7.
   PubMedGoogle Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi:10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14(4):847–56. doi:10.1158/1535-7163.MCT-14-0983.
   PubMed Web of Science ®Google Scholar
• High TMB predicts immunotherapy benefit. Cancer Discov. 2018;8(6):668. doi:10.1158/2159-8290.CD-NB2018-048.
   PubMed Web of Science ®Google Scholar
• Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15(6):382–96. doi:10.1038/s41571-018-0006-2.
   PubMed Web of Science ®Google Scholar
• Kluger HM, Tawbi HA, Ascierto ML, Bowden M, Callahan MK, Cha E, Chen HX, Drake CG, Feltquate DM, Ferris RL, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8:1. doi:10.1136/jitc-2019-000398.
   Web of Science ®Google Scholar
• Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489–96. doi:10.1016/S1470-2045(04)01528-1.
   PubMed Web of Science ®Google Scholar
• Kamath AV. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. Drug Discov Today Technol. 2016;21-22:75–83. doi:10.1016/j.ddtec.2016.09.004.
   PubMedGoogle Scholar
• Zhou H, Mascelli MA. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011;51(1):359–72. doi:10.1146/annurev-pharmtox-010510-100510.
   PubMedGoogle Scholar
• Gong J, Chehrazi-Raffle A, Placencio-Hickok V, Guan M, Hendifar A, Salgia R. The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies. Clin Transl Med. 2019:8. doi:10.1186/s40169-019-0225-x.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Francino MP. Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances. Front Microbiol. 2016:6. doi:10.3389/fmicb.2015.01543.
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Gramenitskaya D, Altmann DM, Boyton RJ, Mullish BH, Marchesi JR, Bower M. Antibiotic therapy and outcome from immune-checkpoint inhibitors. J Immunother Cancer. 2019:7. doi:10.1186/s40425-019-0775-x.
   PubMedGoogle Scholar
• Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.2785.
   PubMed Web of Science ®Google Scholar
• Kim H, Lee JE, Hong SH, Lee MA, Kang JH, Kim I. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: A retrospective study. BMC Cancer. 2019;19(1):1100. doi:10.1186/s12885-019-6267-z.
   PubMed Web of Science ®Google Scholar
• Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525–31. doi:10.1016/j.annonc.2020.01.006.
   PubMed Web of Science ®Google Scholar
• Zhao S, Gao G, Li W, Li X, Zhao C, Jiang T, Jia Y, He Y, Li A, Su C, et al. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in chinese patients with advanced non-small cell lung cancer. Lung Cancer. 2019;130:10–17. doi:10.1016/j.lungcan.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Ahmed J, Kumar A, Parikh K, Anwar A, Knoll BM, Puccio C, Chun H, Fanucchi M, Lim SH. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7:11. doi:10.1080/2162402X.2018.1507670.
   Web of Science ®Google Scholar
• Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of Oncology. 2018;29(6):1437–44. doi:10.1093/annonc/mdy103.
   PubMed Web of Science ®Google Scholar
• Schett A, Rothschild SI, Curioni-Fontecedro A, Krähenbühl S, Früh M, Schmid S, Driessen C, Joerger M. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors. Cancer Chemother Pharmacol. 2020;85(1):121–31. doi:10.1007/s00280-019-03993-1.
   PubMed Web of Science ®Google Scholar
• Elkrief A, El Raichani L, Richard C, Messaoudene M, Belkaid W, Malo J, Belanger K, Miller W, Jamal R, Letarte N, et al. Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. OncoImmunology. 2019;8(4):e1568812. doi:10.1080/2162402X.2019.1568812.
   PubMed Web of Science ®Google Scholar
• Tinsley N, Zhou C, Tan G, Rack S, Lorigan P, Blackhall F, Krebs M, Carter L, Thistlethwaite F, Graham D, et al. Cumulative antibiotic use significantly decreases efficacy of checkpoint inhibitors in patients with advanced cancer. Oncologist. 2020;25(1):55–63. doi:10.1634/theoncologist.2019-0160.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martínez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36(28):2872–78. doi:10.1200/JCO.2018.79.0006.
   PubMed Web of Science ®Google Scholar
• Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. Journal of Thoracic Oncology. 2018;13(11):1771–75. doi:10.1016/j.jtho.2018.06.004.
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019;37(22):1927–34. doi:10.1200/JCO.19.00189.
   PubMed Web of Science ®Google Scholar
• Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, et al. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 2019;4(1):e000457. doi:10.1136/esmoopen-2018-000457.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract. 2019;25(3):762–64. doi:10.1177/1078155218771152.
   PubMed Web of Science ®Google Scholar
• Homicsko K, Richtig G, Tuchmann F, Tsourti Z, Hanahan D, Coukos G, Wind-Rotolo M, Richtig E, Zygoura P, Holler C, et al. Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients. Annals of Oncology. 2018;29:40–40. doi:10.1093/annonc/mdy511.001.
   Web of Science ®Google Scholar
• Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. J Immunother Cancer. 2018;6(1):64. doi:10.1186/s40425-018-0375-1.
   PubMedGoogle Scholar
• Afzal MZ, Dragnev K, Sarwar T, Shirai K. Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors. Lung Cancer Manag. 2019;8:2. doi:10.2217/lmt-2018-0016.
   Web of Science ®Google Scholar
• Abid MB. Could the menagerie of the gut microbiome really cure cancer? hope or hype. J Immunother Cancer. 2019;7(1):92. doi:10.1186/s40425-019-0561-9.
   PubMedGoogle Scholar
• Lagier J, Million M, Hugon P, Armougom F, Raoult D. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol. 2012;2:136. doi:10.3389/fcimb.2012.00136.
   PubMed Web of Science ®Google Scholar
• Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020;159(2):167–77. doi:10.1111/imm.13141.
   PubMed Web of Science ®Google Scholar
• Myers G. Immune-related adverse events of immune checkpoint inhibitors: A brief review. Curr Oncol. 2018;25(5):342–47. doi:10.3747/co.25.4235.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–11. doi:10.1002/cncr.30642.
   PubMed Web of Science ®Google Scholar
• Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J ImmunoTher Cancer. 2019;7(1):306. doi:10.1186/s40425-019-0805-8.
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2–13. doi:10.1016/j.mce.2010.04.005.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zheng SG. Hall of fame among pro-inflammatory cytokines: interleukin-6 gene and its transcriptional regulation mechanisms. Front Immunol. 2016;7:604. doi:10.3389/fimmu.2016.00604.
   PubMed Web of Science ®Google Scholar
• Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51. doi:10.1186/s40425-018-0371-5.
   PubMed Web of Science ®Google Scholar
• Medina P, Jeffers KD, Trinh VA, Harvey RD. The role of pharmacists in managing adverse events related to immune checkpoint inhibitor therapy. J Pharm Prac. 2019:0897190019885230. doi:10.1177/0897190019885230.
   Web of Science ®Google Scholar
• Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, Sellers MC, Balaji A, Ben-Betzalel G, Hajir I, et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol. 2020;38(6):576–83. doi:10.1200/JCO.19.01674.
   PubMed Web of Science ®Google Scholar
• Biswas S, Benedict SH, Lynch SG, LeVine SM. Potential immunological consequences of pharmacological suppression of gastric acid production in patients with multiple sclerosis. BMC Med. 2012;10:57. doi:10.1186/1741-7015-10-57.
   PubMed Web of Science ®Google Scholar
• Nguyen QP, Nomura M, Matsumoto S, Muto M. MO3-10-1 - the effect of proton pump inhibitors on the efficacy of nivolumab monotherapy in different types of cancer. Ann Oncol. 2019;30:vi115. doi:10.1093/annonc/mdz338.107.
   Web of Science ®Google Scholar
• Trabolsi A, Winter M, Rodriguez E. Proton pump inhibitors and response to immune check-point inhibitors: single center study. JCO. 2019;37(15):e14092. doi:10.1200/JCO.2019.37.15_suppl.e14092.
   Web of Science ®Google Scholar
• Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25(22):2706–19. doi:10.3748/wjg.v25.i22.2706.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Goodrich JK, Maxan M, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56. doi:10.1136/gutjnl-2015-310861.
   PubMed Web of Science ®Google Scholar
• Lugini L, Federici C, Borghi M, Azzarito T, Marino ML, Cesolini A, Spugnini EP, Fais S. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhibit Med Chem. 2016;31(4):538–45. doi:10.3109/14756366.2015.1046062.
   PubMed Web of Science ®Google Scholar
• Seethapathy H, Zhao S, Chute DF, Zubiri L, Oppong Y, Strohbehn I, Cortazar FB, Leaf DE, Mooradian MJ, Villani A, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol. 2019;14(12):1692–700. doi:10.2215/CJN.00990119.
   PubMed Web of Science ®Google Scholar
• Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Dufour E, Mutlu GM, Budigner GS, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3. doi:10.7554/eLife.02242.
   PubMed Web of Science ®Google Scholar
• Verdura S, Cuyàs E, Martin-Castillo B, Menendez JA. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy. Oncoimmunology. 2019;8:10. doi:10.1080/2162402X.2019.1633235.
   Web of Science ®Google Scholar
• Oliveras-Ferraros C, Cufí S, Vazquez-Martin A, Menendez OJ, Bosch-Barrera J, Martin-Castillo B, Joven J, Menendez JA. Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle. 2012;11(5):865–70. doi:10.4161/cc.11.5.19252.
   PubMed Web of Science ®Google Scholar
• Ne S, Av M, Rd WXZ. Gm D. Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res. 2016;5(1):9–16. doi:10.1158/2326-6066.CIR-16-0103.
   PubMed Web of Science ®Google Scholar
• Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Jakubikova L, Cernovska M, Hrnciarik M, Jirousek M, et al. Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer. Anticancer Res. 2020;40(4):2209–17. doi:10.21873/anticanres.14182.
   PubMed Web of Science ®Google Scholar
• Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K. Study protocol: phase-ib trial of nivolumab combined with metformin for refractory/recurrent solid tumors. Clin Lung Cancer. 2018;19(6):e861–e864. doi:10.1016/j.cllc.2018.07.010.
   PubMed Web of Science ®Google Scholar
• Ketwaroo GA, Cheng V, Lembo A. Opioid-induced bowel dysfunction. Curr Gastroenterol Rep. 2013;15(9):344. doi:10.1007/s11894-013-0344-2.
   PubMedGoogle Scholar
• Taylor A. Revealing a brain-gut microbiome connection following chronic opioid treatment. The Journal of Pain. 2018;19(3):S1. doi:10.1016/j.jpain.2017.12.012.
   PubMedGoogle Scholar
• Acharya C, Betrapally NS, Gillevet PM, Sterling RK, Akbarali H, White MB, Ganapathy D, Fagan A, Sikaroodi M, Bajaj JS. Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(2):319–31. doi:10.1111/apt.13858.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Sindberg G, Wang F, Meng J, Sharma U, Zhang L, Dauer P, Chen C, Dalluge J, Johnson T, et al. Opioid-induced gut microbial disruption and bile dysregulation leads to gut barrier compromise and sustained systemic inflammation. Mucosal Immunol. 2016;9(6):1418–28. doi:10.1038/mi.2016.9.
   PubMed Web of Science ®Google Scholar
• Ren M, Lotfipour S. The role of the gut microbiome in opioid use. Behav Pharmacol. 2020;31:2. doi:10.1097/FBP.0000000000000538.
   Web of Science ®Google Scholar
• Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, DuPont HL, Garey KW. Moderate to high use of opioid analgesics are associated with an increased risk of clostridium difficile infection. Am J Med Sci. 2012;343(4):277–80. doi:10.1097/MAJ.0b013e31822f42eb.
   PubMed Web of Science ®Google Scholar
• Iglesias-Santamaría A. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol. 2020. doi:10.1007/s12094-019-02282-w.
   PubMed Web of Science ®Google Scholar